Now, the hurdle they’re jumping? Antibody research is a bit like a lab marathon. It’s slow, needs a ton of controlled repetition, and that puts the brakes on discovering new treatments pronto. IBM and Boehringer Ingelheim are rolling out the big guns — generative AI. This whiz-bang tech cooks up molecules that haven’t had their moment in the spotlight, kicks out the no-go candidates, and lets researchers zoom in on the promising ones. Efficiency? You bet.
